Semaglutide is an FDA-approved obesity treatment
In a pilot trial, 12 children with severe IBD that had not responded to other therapies were given 36 grams of oral NAG daily
The 3D printing technologies in nanosponges offer numerous advantages, including protection against degradation, improved solubility, targeted delivery, and even the potential for magnetization
These include nausea, vomiting, diarrhea, constipation, and abdominal pain
Individuals who may be at greater risk include: Those with a pre-existing diagnosis of osteoarthritis, rheumatoid arthritis, or other inflammatory joint conditions Patients with obesity-related joint loading, particularly affecting the knees, hips, and lower back Older adults, in whom musculoskeletal complaints are more prevalent at baseline Individuals experiencing rapid weight loss, which may transiently alter joint mechanics and gait, particularly in the lower limbs this is a theoretical consideration based on general musculoskeletal principles rather than retatrutide-specific evidence Significant weight reduction one of retatrutide's primary therapeutic effects is generally associated with reduced mechanical load on weight-bearing joints , which may improve joint symptoms over time in individuals with obesity-related arthropathy
